Optimization of genetics to create therapies for metastatic (stage IV) non-small-cell lung cancer

Bibliography

• Fossella F, Pereira JR, von Pawel J, Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003;21(16):3016-24
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Parikh P, von Pawel J, Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26(21):3543-51
   PubMed Web of Science ®Google Scholar
• Cobo M, Isla D, Massuti B, Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 2007;25(19):2747-54
   PubMed Web of Science ®Google Scholar
• Guha U, Chaerkady R, Marimuthu A, Comparisons of tyrosine phosphorylated proteins in cells expressing lung cancer-specific alleles of EGFR and KRAS. Proc Natl Acad Sci USA 2008;105(37):14112-17
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bell DW, Sordella R, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350(21):2129-39
   PubMed Web of Science ®Google Scholar
• Paez JG, Janne PA, Lee JC, EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304(5676):1497-500
   PubMed Web of Science ®Google Scholar
• Pao W, Miller V, Zakowski M, EGF receptor gene mutations are common in lung cancers from ‘never smokers’ and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004;101(36):13306-11
   PubMed Web of Science ®Google Scholar
• Sequist LV, Martins RG, Spigel D, First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008;26(15):2442-9
   PubMed Web of Science ®Google Scholar
• Taron M, Ichinose Y, Rosell R, Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res 2005;11(16):5878-85
   PubMed Web of Science ®Google Scholar
• Costa DB, Kobayashi S, Tenen DG, Huberman MS. Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. Lung Cancer 2007;58(1):95-103
   PubMed Web of Science ®Google Scholar
• Lafarge S, Sylvain V, Ferrara M, Bignon YJ. Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway. Oncogene 2001;20(45):6597-606
   PubMed Web of Science ®Google Scholar
• Husain A, He G, Venkatraman ES, Spriggs DR. BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). Cancer Res 1998;58(6):1120-3
   PubMed Web of Science ®Google Scholar
• Bhattacharyya A, Ear US, Koller BH, The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 2000;275(31):23899-903
   PubMed Web of Science ®Google Scholar
• Abbott DW, Thompson ME, Robinson-Benion C, BRCA1 expression restores radiation resistance in BRCA1-defective cancer cells through enhancement of transcription-coupled DNA repair. J Biol Chem 1999;274(26):18808-12
   PubMed Web of Science ®Google Scholar
• Mullan PB, Quinn JE, Gilmore PM, BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents. Oncogene 2001;20(43):6123-31
   PubMed Web of Science ®Google Scholar
• Quinn JE, Kennedy RD, Mullan PB, BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 2003;63(19):6221-8
   PubMed Web of Science ®Google Scholar
• Chabalier C, Lamare C, Racca C, BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance. Cell Cycle 2006;5(9):1001-7
   PubMed Web of Science ®Google Scholar
• Quinn JE, James CR, Stewart GE, BRCA1 mRNA Expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin Cancer Res 2007;13(24):7413-20
   PubMed Web of Science ®Google Scholar
• Wang L, Wei J, Qian X, ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel. BMC Cancer 2008;8:97
   PubMed Web of Science ®Google Scholar
• Taron M, Rosell R, Felip E, BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet 2004;13(20):2443-9
   PubMed Web of Science ®Google Scholar
• Weberpals J, Garbuio K, O'Brien A, The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer. Int J Cancer 2009;124(4):806-15
   PubMed Web of Science ®Google Scholar
• Margeli M, Cirauqui B, Castella E, The prognostic value of BRCA1 mRNA expression levels following neoadjuvant chemotherapy in breast cancer. PLoS ONE 2010; In press
   PubMed Web of Science ®Google Scholar
• Harper JW, Elledge SJ. The DNA damage response: ten years after. Mol Cell 2007;28(5):739-45
   PubMed Web of Science ®Google Scholar
• Wang B, Matsuoka S, Ballif BA, Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response. Science 2007;316(5828):1194-8
   PubMed Web of Science ®Google Scholar
• Sobhian B, Shao G, Lilli DR, RAP80 targets BRCA1 to specific ubiquitin structures at DNA damage sites. Science 2007;316(5828):1198-202
   PubMed Web of Science ®Google Scholar
• Kim H, Chen J, Yu X. Ubiquitin-binding protein RAP80 mediates BRCA1-dependent DNA damage response. Science 2007;316(5828):1202-5
   PubMed Web of Science ®Google Scholar
• Rosell R, Perez-Roca L, Sanchez JJ, Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression. PLoS ONE 2009;4(5):e5133
   PubMed Web of Science ®Google Scholar
• Wang B, Elledge SJ. Ubc13/Rnf8 ubiquitin ligases control foci formation of the Rap80/Abraxas/Brca1/Brcc36 complex in response to DNA damage. Proc Natl Acad Sci USA 2007;104(52):20759-63
   PubMed Web of Science ®Google Scholar
• Yan J, Kim YS, Yang XP, The ubiquitin-interacting motif containing protein RAP80 interacts with BRCA1 and functions in DNA damage repair response. Cancer Res 2007;67(14):6647-56
   PubMed Web of Science ®Google Scholar
• Schiller JH, Harrington D, Belani CP, Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346(2):92-8
   PubMed Web of Science ®Google Scholar
• Deeb KK, Michalowska AM, Yoon CY, Identification of an integrated SV40 T/t-antigen cancer signature in aggressive human breast, prostate, and lung carcinomas with poor prognosis. Cancer Res 2007;67(17):8065-80
   PubMed Web of Science ®Google Scholar
• Rosell R, Skrzypski M, Jassem E, BRCA1: A novel prognostic factor in resected non-small-cell lung cancer. PLoS ONE 2007;2(11):e1129
   PubMed Web of Science ®Google Scholar
• Boukovinas I, Papadaki C, Mendez P, Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients. PLoS ONE 2008;3(11):e3695
   PubMed Web of Science ®Google Scholar
• Tamura K, Okamoto I, Kashii T, Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403). Br J Cancer 2008;98(5):907-14
   PubMed Web of Science ®Google Scholar
• Rosell R, Moran T, Queralt C, Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361(10):958-67
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu YL, Thongprasert S, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361(10):947-57
   PubMed Web of Science ®Google Scholar
• Jackman DM, Miller VA, Cioffredi LA, Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res 2009;15(16):5267-73
   PubMed Web of Science ®Google Scholar
• Riely GJ, Pao W, Pham D, Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 2006;12(3 Pt 1):839-44
   PubMed Web of Science ®Google Scholar
• Rosell R, Viteri S, Molina MA, Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer. Curr Opin Oncol 2010;22:112-20
   Google Scholar
• Nguyen KS, Kobayashi S, Costa DB. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer 2009;10(4):281-9
   PubMed Web of Science ®Google Scholar
• Zhou W, Ercan D, Chen L, Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 2009;462(7276):1070-4
   PubMed Web of Science ®Google Scholar
• Maheswaran S, Sequist LV, Nagrath S, Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008;359(4):366-77
   PubMed Web of Science ®Google Scholar
• Inukai M, Toyooka S, Ito S, Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res 2006;66(16):7854-8
   PubMed Web of Science ®Google Scholar
• Kuang Y, Rogers A, Yeap BY, Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer. Clin Cancer Res 2009;15(8):2630-6
   PubMed Web of Science ®Google Scholar
• Smouse JH, Cibas ES, Janne PA, EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer. Cancer Cytopathol 2009;117(1):67-72
   Web of Science ®Google Scholar
• Molina-Vila MA, Bertran-Alamillo J, Reguart N, A sensitive method for detecting EGFR mutations in non-small cell lung cancer samples with few tumor cells. J Thorac Oncol 2008;3(11):1224-35
   PubMed Web of Science ®Google Scholar
• Morita S, Okamoto I, Kobayashi K, Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations. Clin Cancer Res 2009;15(13):4493-8
   PubMed Web of Science ®Google Scholar
• Miyazawa H, Tanaka T, Nagai Y, Peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based detection test for gefitinib-refractory T790M epidermal growth factor receptor mutation. Cancer Sci 2008;99(3):595-600
   PubMed Web of Science ®Google Scholar
• Yu J, Kane S, Wu J, Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Clin Cancer Res 2009;15(9):3023-8
   PubMed Web of Science ®Google Scholar
• Motoi N, Szoke J, Riely GJ, Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol 2008;32(6):810-27
   PubMedGoogle Scholar
• De Oliveira Duarte Achcar R, Nikiforova MN, Yousem SA. Micropapillary lung adenocarcinoma: EGFR, K-ras, and BRAF mutational profile. Am J Clin Pathol 2009;131(5):694-700
   PubMed Web of Science ®Google Scholar